BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Piper Jaffray Companies cut their FY2021 EPS estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, May 21st. Piper Jaffray Companies analyst T. Van. Buren now anticipates that the biotechnology company will earn ($1.55) per share for the year, down from their previous estimate of ($1.30). Piper Jaffray Companies currently has a “Buy” rating and a $15.00 target price on the stock. Piper Jaffray Companies also issued estimates for BioCryst Pharmaceuticals’ FY2022 earnings at ($1.05) EPS and FY2023 earnings at ($0.05) EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.28). The company had revenue of $5.89 million during the quarter, compared to the consensus estimate of $2.92 million. BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%.

Several other equities research analysts also recently weighed in on the stock. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 2nd. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday. Finally, Barclays raised their price target on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 2nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.56.

Shares of BCRX opened at $3.32 on Thursday. The company has a market cap of $390.51 million, a P/E ratio of -3.39 and a beta of 1.71. The company has a quick ratio of 1.76, a current ratio of 1.77 and a debt-to-equity ratio of 2.38. BioCryst Pharmaceuticals has a twelve month low of $3.10 and a twelve month high of $9.95.

A number of hedge funds have recently modified their holdings of BCRX. JGP Global Gestao de Recursos Ltda. boosted its stake in shares of BioCryst Pharmaceuticals by 8.5% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 25,742 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 2,018 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 4.9% during the 1st quarter. AQR Capital Management LLC now owns 46,870 shares of the biotechnology company’s stock worth $382,000 after acquiring an additional 2,185 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of BioCryst Pharmaceuticals by 14.5% during the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 2,453 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1.6% during the 1st quarter. ClariVest Asset Management LLC now owns 234,898 shares of the biotechnology company’s stock worth $1,913,000 after acquiring an additional 3,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of BioCryst Pharmaceuticals by 6.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 71,800 shares of the biotechnology company’s stock worth $585,000 after acquiring an additional 4,151 shares during the last quarter. Institutional investors own 92.26% of the company’s stock.

In related news, CFO Thomas R. Staab II sold 7,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $7.30, for a total value of $56,575.00. Following the sale, the chief financial officer now owns 140,426 shares in the company, valued at $1,025,109.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas R. Staab II sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $8.81, for a total transaction of $66,075.00. Following the completion of the sale, the insider now owns 140,176 shares in the company, valued at approximately $1,234,950.56. The disclosure for this sale can be found here. Insiders sold 75,000 shares of company stock worth $583,298 in the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Story: Why do corrections happen?

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.